Study in Patients With Asthma

Dey Pharma

Status and phase: Completed; Phase 2

Conditions: Asthma

Treatments: Drug: Formoterol Fumarate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00215358

DL-048

Details and patient eligibility

About

The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control drug.

Sex: All

Ages: 12 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Require regular use of an inhaled Beta-2-selective adrenergic agent

Exclusion criteria

• Active acute or chronic disorders of the respiratory system within one month prior to screening
• Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history
• Recent surgical interventions such as lung lobectomy or resection (< one year), or cardiothoracic interventions
• Life-threatening systemic and debilitating diseases.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind